Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial—ECOG-ACRIN EA6134

Combination programmed cell death protein 1/cytotoxic T-cell lymphocyte-4–blockade and dual BRAF/MEK inhibition have each shown significant clinical benefit in patients with BRAFV600-mutant metastatic melanoma, leading to broad regulatory approval. Little prospective data exist to guide the choice o...

Descripción completa

Detalles Bibliográficos
Autores principales: Atkins, Michael B., Lee, Sandra J., Chmielowski, Bartosz, Tarhini, Ahmad A., Cohen, Gary I., Truong, Thach-Giao, Moon, Helen H., Davar, Diwakar, O'Rourke, Mark, Stephenson, Joseph J., Curti, Brendan D., Urba, Walter J., Brell, Joanna M., Funchain, Pauline, Kendra, Kari L., Ikeguchi, Alexandra P., Jaslowski, Anthony, Bane, Charles L., Taylor, Mark A., Bajaj, Madhuri, Conry, Robert M., Ellis, Robert J., Logan, Theodore F., Laudi, Noel, Sosman, Jeffrey A., Crockett, David G., Pecora, Andrew L., Okazaki, Ian J., Reganti, Sowjanya, Chandra, Sunandana, Guild, Samantha, Chen, Helen X., Streicher, Howard Z., Wolchok, Jedd D., Ribas, Antoni, Kirkwood, John M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2023
Materias:
RAPID COMMUNICATIONS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9839305/
https://www.ncbi.nlm.nih.gov/pubmed/36166727
http://dx.doi.org/10.1200/JCO.22.01763

Ejemplares similares

Ejemplares similares